Results 21 to 30 of about 1,414 (186)
Clinical Interventions in Aging, 2017 Chunmei Cui, Hong Lu Department of Ophthalmology, Beijing Chao-Yang Hospital, Beijing, China Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD). Although
Cui C, Lu H
doaj +2 more sources
Anti-scarring effects of conbercept on human Tenon’s fibroblasts: comparisons with bevacizumab
BMC Ophthalmology, 2023 Background Safely inhibiting the formation of scar in the glaucoma filtration surgery (GFS) has always been an issue for clinical glaucoma doctors. Anti-vascular endothelial growth factor (VEGF) agents can reduce angiogenesis, and anti-placental growth ...
Lei Zuo +3 more
doaj +3 more sources
Successful Use of Conbercept to Treat Choroidal Neovascularization: A Case Report
Case Reports in Ophthalmology, 2022 Chronic urticaria is a dermatological condition characterized by the appearance of wheals or angioedema longer than 6 weeks. It could cause serious complications such as laryngeal edema, vasculitis, and diarrhea. However, the pathologic changes of the ocular fundus caused by chronic urticaria are rarely reported.
Jin Yang, Zheng Liu, Tao Liu
openaire +4 more sources
Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis [PDF]
International Journal of Ophthalmology, 2023 AIM: To evaluate and compare the anatomical and functional outcomes and negative effects of the three anti-vascular endothelial growth factor (VEGF) drugs in the treatment of macular edema (ME) due to retinal vein occlusion (RVO) based on the evidence ...
Qiu Xing +3 more
doaj +3 more sources
BMC Ophthalmology, 2017 Background To compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice. Methods This was a retrospective study.
Yule Xu +4 more
doaj +2 more sources
Conbercept Treatment for Heart-Shaped Vascular Intertwined Nets in Macular Neovascularization: Anti-VEGF Drug Therapy Strategy Based on Vascular Geometry Diagnosed by OCTA. [PDF]
Clin Case RepA 63‐year‐old male with a history of hypertension and diabetes developed acute vision loss, which was attributed to macular neovascularization secondary to hypertensive retinopathy. Optical coherence tomography angiography revealed unusual heart‐shaped, intertwined vascular nets, informing the choice of Conbercept for intravitreal injection.
Ou S, Shi F, Cai M, Wu Y.
europepmc +4 more sources
Profile of conbercept in the treatment of neovascular age-related macular degeneration
Drug Design, Development and Therapy, 2015 Xinmin Lu,1 Xiaodong Sun1–31Department of Ophthalmology, Shanghai First People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2Eye Research Institute of Shanghai Jiao Tong University,
Lu XM, Sun XD
doaj +1 more source
Drug Design, Development and Therapy, 2018 Luping Wang,1 Canwei Zhang,2 Rui Hua3 1Department of Ophthalmology, University of Bonn, Bonn, Germany; 2Department of Ophthalmology, Weifang Eye Hospital, Weifang, People’s Republic of China; 3Department of Ophthalmology, First Hospital of China ...
Wang LP, Zhang CW, Hua R
doaj +1 more source
Journal of Ophthalmology, 2020 Purpose. To evaluate the ocular pharmacokinetic properties of subretinal conbercept injection in vitrectomized rabbit eyes and to compare them with those by intravitreal injection. Methods.
Teng-teng Yao +6 more
doaj +2 more sources
An update on conbercept to treat wet age-related macular degeneration
Drugs of Today, 2020 Wet age-related macular degeneration (w-AMD) represents the main cause of vision loss in the elderly in the western countries. The important role displayed by vascular endothelial growth factor (VEGF) in the pathogenesis of this disease has been largely demonstrated.
Lorenzo Ferro Desideri +2 more
openaire +4 more sources